Albert Robichaud is Chief Scientific Officer of Sage Therapeutics, Inc.. Currently has a direct ownership of 145,553 shares of SAGE, which is worth approximately $752,509. The most recent transaction as insider was on Feb 03, 2023, when has been sold 1,127 shares (Common Stock) at a price of $44.16 per share, resulting in proceeds of $49,768. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 146K
0% 3M change
0% 12M change
Total Value Held $752,509

Albert Robichaud Transaction History

Date Transaction Value Shares Traded Shares Held Form
Feb 03 2023
SELL
Payment of exercise price or tax liability
$49,768 $44.16 p/Share
1,127 Reduced 0.77%
145,553 Common Stock
Feb 03 2023
BUY
Grant, award, or other acquisition
-
3,375 Added 2.25%
146,680 Common Stock
Oct 19 2021
SELL
Payment of exercise price or tax liability
$44,964 $40.29 p/Share
1,116 Reduced 0.78%
142,619 Common Stock
Oct 19 2021
BUY
Grant, award, or other acquisition
-
3,800 Added 2.58%
143,735 Common Stock
Jun 15 2021
SELL
Payment of exercise price or tax liability
$67,267 $58.8 p/Share
1,144 Reduced 0.81%
139,651 Common Stock
Jun 15 2021
BUY
Grant, award, or other acquisition
-
4,000 Added 2.76%
140,795 Common Stock
AR

Albert Robichaud

Chief Scientific Officer
Cambridge, MA

Track Institutional and Insider Activities on SAGE

Follow Sage Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells SAGE shares.

Notify only if

Insider Trading

Get notified when an Sage Therapeutics, Inc. insider buys or sells SAGE shares.

Notify only if

News

Receive news related to Sage Therapeutics, Inc.

Track Activities on SAGE